🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Rimini Breakstone

Rimini Breakstone

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer”.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.49040

N/A

3.5DataRank · unranked

127 citations

Fang‐Shu Ou, Tyler Zemla, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone +11 more

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps265

N/A

0DataRank · unranked

8 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo Ian Hu +6 more

P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Annals of Oncology(2023)10.1016/j.annonc.2023.04.284

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zelan Hu +7 more

Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3526

N/A

0DataRank · unranked

0 citations

Andrew Elliott, Marzia Capelletti, Emil Lou, John L. Marshall, Heinz‐Josef Lenz +10 more